Suzanne Marshall, PA
Medical · Houston, TXNPI 1053696468
Payments from drug & device makers
Across 273 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Dexcom, Inc.$307
- GSK$216
- Boehringer Ingelheim$187
- Pfizer$178
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,66198%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $1,149 |
| AbbVie | 74 | $1,020 |
| Dexcom, Inc. | 9 | $307 |
| GSK | 14 | $216 |
| Boehringer Ingelheim | 10 | $187 |
| Pfizer | 8 | $178 |
| Bayer | 7 | $177 |
| Lilly USA, LLC | 13 | $172 |
| Johnson & Johnson | 11 | $163 |
| Astellas Pharma US Inc | 6 | $160 |
| Amarin Pharma, Inc. | 7 | $110 |
| Esperion Therapeutics, Inc. | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Amgen | 5 | $77 |
| Phathom Pharmaceuticals, Inc. | 3 | $70 |
| Antares Pharma, Inc. | 4 | $64 |
| Merck | 4 | $59 |
| Abbott | 2 | $44 |
| AstraZeneca | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Coloplast | 1 | $30 |
| Novartis | 2 | $29 |
| Si-bone, Inc. | 1 | $26 |
| Heartflow, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$233
- QULIPTA$125
- UBRELVY$125
- DEXCOM G7 GSS (161)$119
- Wegovy$114
- DEXCOM G6 TRANSMITTER$111
How this compares
$4,746 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $74,043 |
| MounjaroTirzepatide | 32 | $38,870 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $18,237 |
| Xigduo XrDapaglifloz Propaned/Metformin | 17 | $17,193 |
| VascepaIcosapent Ethyl | 20 | $11,098 |
| EliquisApixaban | 11 | $9,997 |
| MyrbetriqMirabegron | 14 | $9,781 |
| JanuviaSitagliptin Phosphate | 13 | $8,565 |
| SynthroidLevothyroxine Sodium | 58 | $3,732 |
| Rosuvastatin Calcium | 203 | $2,753 |
| Levothyroxine Sodium | 168 | $1,828 |
| ValacyclovirValacyclovir Hcl | 27 | $1,555 |
| Metoprolol Succinate | 111 | $1,497 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $1,493 |
| Estradiol | 12 | $1,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,149 | $74,04351 claims |
| Lilly USA, LLCMounjaro | $172 | $38,87032 claims |
| Boehringer IngelheimSynjardy Xr | $187 | $18,23717 claims |
| PfizerEliquis | $178 | $9,99711 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $9,78114 claims |
| MerckJanuvia | $59 | $8,56513 claims |
| AbbVieSynthroid | $1,020 | $3,73258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.
Other medical in Houston
- Olga RodziyenskaHouston$65K
- Kathleen HoganHouston$26K
- Omni McCluneyHouston$18K
- Carl MayberryHouston$18K
- Carley BuddenbaumHouston$16K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.